Cassava Sciences Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while JPMorgan Diversified Return International Eqty ETF trades at $73.52. The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JPIN | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $76.96 |
52-Week Low | $1.09 | $63.14 |
Enterprise Value | -$33.43M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.33, showing minimal daily movement with a 0.08% gain. The technical outlook is neutral to bearish, with moving averages signaling caution, while oscillators remain neutral. Key support is at $72 and resistance at $73-$74. The fund, launched in 2014, provides broad exposure to international value stocks, but fundamental metrics like P/E and profitability ratios are unavailable in the provided data.
The outlook for JPIN is neutral, with technical indicators mixed and no clear directional bias. Investment opportunity lies in its diversified international equity exposure, but risks include market volatility and reliance on global economic conditions. The absence of recent fundamental data limits a comprehensive assessment, requiring investors to monitor broader market trends and fund-specific updates for catalysts.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →